Stockscreener 앱 받기
0.711
2.38%
0.0165
시간 외 거래:
.72
0.009
+1.27%
전일 마감가:
$0.6945
열려 있는:
$0.71
하루 거래량:
945.27K
Relative Volume:
1.35
시가총액:
$29.96M
수익:
-
순이익/손실:
$-35.58M
주가수익비율:
-0.2683
EPS:
-2.65
순현금흐름:
$-42.82M
1주 성능:
-2.87%
1개월 성능:
-23.79%
6개월 성능:
-50.28%
1년 성능:
-32.92%
1일 변동 폭
$0.7038
$0.755
1주일 범위
$0.6573
$0.779
52주 변동 폭
$0.6573
$3.02
Iterum Therapeutics Plc Stock (ITRM) Company Profile
명칭
Iterum Therapeutics Plc
전화
(872) 225-6077
주소
3 DUBLIN LANDINGS, DUBLIN 1
ITRM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ITRM
Iterum Therapeutics Plc
|
0.711 | 29.72M | 0 | -35.58M | -42.82M | -2.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Iterum Therapeutics Plc Stock (ITRM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-05-28 | 업그레이드 | Gabelli & Co | Sell → Hold |
| 2021-03-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-06-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-01-21 | 다운그레이드 | Gabelli & Co | Buy → Sell |
| 2019-12-11 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-06-21 | 개시 | H.C. Wainwright | Buy |
모두보기
Iterum Therapeutics Plc 주식(ITRM)의 최신 뉴스
Iterum Therapeutics plc stock trend outlook and recovery pathReversal Pattern Insights with Entry Tips - Newser
Advanced analytics toolkit walkthrough for Iterum Therapeutics plcRetirement Investment Outlook and Return Summary - Newser
Iterum Therapeutics plc (NASDAQ:ITRM) Q2 2025 Earnings Call Transcript - MSN
ITRM Reports Results - AOL.com
ITRM Reports Results - The Motley Fool
Iterum Therapeutics PLC reports results for the quarter ended June 30Earnings Summary - TradingView
Iterum Therapeutics (ITRM) Financial Outlook for 2025 - GuruFocus
Iterum Therapeutics plc SEC 10-Q Report - TradingView
Iterum Therapeutics reports Q2 results, launches ORLYNVAH, extends cash runway to 2026. - AInvest
Iterum Therapeutics to Launch ORLYNVAH™ for Uncomplicated UTIs in August 2025, Reports Q2 Financial Results - Quiver Quantitative
Iterum Therapeutics reports Q2 revenue, cash runway into 2026, ORLYNVAH launch in August. - AInvest
Iterum Earnings Show $13M Cash as Revolutionary UTI Antibiotic ORLYNVAH Readies for Historic Launch - Stock Titan
Price momentum metrics for Iterum Therapeutics plc explainedYearly Trend Summary and Opportunity Breakdown - Newser
Iterum Therapeutics to Announce Q2 2025 Earnings on Aug 5, 2025 - AInvest
Iterum Therapeutics Q2 Earnings Preview: Analysts Expect EPS of $-0.13 - AInvest
How to forecast Iterum Therapeutics plc trends using time seriesBull Market Summary and Recovery Outlook - Newser
What makes Iterum Therapeutics plc stock price move sharplyFree Accurate Technical Trend Reversal Picks - Newser
Will Iterum Therapeutics plc stock recover after recent dropPredictive AI Engine for Smart Investing - Newser
Using Bollinger Bands to evaluate Iterum Therapeutics plcAI Screener Based Stock Summary Report - Newser
Exit strategy if you’re trapped in Iterum Therapeutics plcWealth Accumulation Outlook for Safe Investors - Newser
Real time pattern detection on Iterum Therapeutics plc stockSmart Stock Forecast Using AI Algorithms - Newser
Is Iterum Therapeutics plc showing signs of accumulationHigh Yield Watchlist with Filtered Picks - Newser
How volatile is Iterum Therapeutics plc stock compared to the marketAchieve rapid financial growth with expert help - Jammu Links News
Using economic indicators to assess Iterum Therapeutics plc potentialSteady Return Plan Based on Data Analysis - Newser
What are the technical indicators suggesting about Iterum Therapeutics plcTremendous portfolio expansion - Jammu Links News
What is the dividend policy of Iterum Therapeutics plc stockTremendous financial leverage - Jammu Links News
Is Iterum Therapeutics plc a growth stock or a value stockBreakneck growth rates - Jammu Links News
What drives Iterum Therapeutics plc stock priceAchieve consistent profits with smart trading - Jammu Links News
What is the risk reward ratio of investing in Iterum Therapeutics plc stockGet timely advice on market trends - Jammu Links News
What catalysts could drive Iterum Therapeutics plc stock higher in 2025Access high-yield investment alerts now - Jammu Links News
What institutional investors are buying Iterum Therapeutics plc stockAchieve consistent profits with disciplined trading - Jammu Links News
What analysts say about Iterum Therapeutics plc stockUnlock steady growth with low-risk stocks - Jammu Links News
Why is Iterum Therapeutics plc stock attracting strong analyst attentionUnlock steady growth with low-risk stocks - Jammu Links News
What are the latest earnings results for Iterum Therapeutics plcCapitalize on emerging industry trends - Jammu Links News
How does Iterum Therapeutics plc compare to its industry peersRapidly growing investment returns - Jammu Links News
Intraday pattern recognizer results for Iterum Therapeutics plcDaily Stock Movement Forecast with Accuracy - Newser
Iterum Therapeutics plc Company Revenue and Profit Trends: A Deep DiveFree Real Profit Trade Plan Suggestions - Newser
What moving averages say about Iterum Therapeutics plcShort Term Gain Strategy with AI Logic - Newser
Does Iterum Therapeutics plc stock perform well during market downturnsSwing Trade Alerts That Work - jammulinksnews.com
Iterum aims for early ORLYNVAH launch in August 2025 and eyes expansion in $40M uUTI market - MSN
How to use a screener to detect Iterum Therapeutics plc breakoutsPortfolio Review Summary with Five-Year Outlook - Newser
Iterum Therapeutics Plc (ITRM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):